A Six-month comparative Evaluation of Sodium-Glucose Cotransporter-2 inhibitors and Dipeptidyl Peptidase-4 inhibitors on Weight, Body Mass Index, and Glycemic control in patients with Type 2 Diabetes
Syed Afzal Uddin Biyabani*1, Neelkantreddy Patil1 , Vanishree P. Babladi1 , Pooja V. Salimath1 Hafsa Naema1 , Safa Wasay2 and Syed Raziuddin Faisal3
*1-5Department of Pharmacy Practice, Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Kalaburagi - 585105 (India) 6Department of Pharmacy Practice, Jawaharlal Nehru Technological University, Hyderabad - 500085 (India) 3Department of Pharmacy Practice, Visveswarapura Institute of Pharmaceutical Sciences, Bengaluru - 560070 (India) Corresponding Author: Dr. Syed Afzal Uddin Biyabani: Research Scholar, (Department of Pharmacy Practice), Matoshree Taradevi Rampure Institute of Pharmaceutical Sciences, Kalaburagi, (Karnataka) (India) Contact no.- +91 9393243588 Email-Biyabani786786@gmail.com
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a multifactorial metabolic disorder hallmarked by chronic hyperglycaemia arising from a complex interplay of insulin resistance and β-cell dysfunction, predisposing patients to substantial cardiometabolic and microvascular complications. This six-month prospective, observational cohort study delineates the comparative effects of sodium–glucose cotransporter-2 (SGLT-2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors on anthropometric indices and glycaemic parameters in 145 patients with T2DM attending tertiary care hospitals and affiliated diabetic clinics in Kalaburagi, India. Participants were stratified into two intervention arms: SGLT-2 inhibitors (n = 75) and DPP-4 inhibitors (n = 70). Serial measurements of body weight, body mass index (BMI), fasting blood sugar (FBS), postprandial blood sugar (PPBS), and glycated haemoglobin (HbA1c) were obtained at baseline, three months, and six months